...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmacological sciences. >Antiarrhythmic Properties of a Prior Oral Loading of Amiodarone in In Vivo Canine Coronary Ligation/Reperfusion-Induced Arrhythmia Model: Comparison With Other Class III Antiarrhythmic Drugs.
【24h】

Antiarrhythmic Properties of a Prior Oral Loading of Amiodarone in In Vivo Canine Coronary Ligation/Reperfusion-Induced Arrhythmia Model: Comparison With Other Class III Antiarrhythmic Drugs.

机译：预先口服胺碘酮在体内犬冠状动脉结扎/再灌注引起的心律不齐模型中的抗心律不齐特性：与其他III类抗心律不齐药物的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Amiodarone, which is generally classified as class III antiarrhythmic drug in the Vaughan Williams classification, is widely used for the treatments of refractory arrhythmias. However, we previously reported that intravenous infusion of amiodarone (6.67 mg/kg per hour) did not suppress arrhythmias induced by coronary ligation/reperfusion in dogs. In this study, we examined effects of a prior oral loading of amiodarone on arrhythmias induced by coronary ligation/reperfusion. Sixteen female beagle dogs (8.5 - 12.5 kg) were divided into two groups; one group was given amiodarone (40 mg/kg, orally, n = 8), and the other was given empty gelatin capsules (n = 8) 2 h before the operation. Dogs were anesthetized with pentobarbital and artificially ventilated. The left chest was opened, and the left anterior descending coronary artery was ligated for 30 min and then reperfused. The mean plasma concentration of amiodarone was over 1.3 mug/ml. Although the prior oral loading of amiodarone did not change the QT interval, amiodarone suppressed the number of ectopic beats during coronary ligation and the incidence of ventricular fibrillation during coronary ligation and reperfusion periods (P<0.05 vs control group). In conclusion, a prior oral loading of amiodarone suppressed arrhythmias induced by coronary ligation/reperfusion with a dose that did not prolong the QT interval. This antiarrhythmic property of amiodarone is different from those of the other class III drugs in that antiarrhythmic effects were accompanied by QT prolongation in our all previous studies.
机译：胺碘酮在沃恩·威廉姆斯分类中通常被分类为III类抗心律不齐药物，被广泛用于治疗难治性心律不齐。但是，我们先前曾报道静脉注射胺碘酮（每小时6.77 mg / kg）不能抑制犬冠状动脉结扎/再灌注引起的心律不齐。在这项研究中，我们检查了事先口服胺碘酮对冠状动脉结扎/再灌注引起的心律不齐的影响。将十六只雌性比格犬（8.5-12.5公斤）分为两组。一组在手术前2小时给予胺碘酮（40 mg / kg，口服，n = 8），另一组给予空明胶胶囊（n = 8）。用戊巴比妥麻醉狗，并人工通气。张开左胸，并结扎左冠状动脉前降支30分钟，然后再灌注。胺碘酮的平均血浆浓度超过1.3杯/毫升。尽管先前口服胺碘酮并没有改变QT间期，但胺碘酮抑制了冠状动脉结扎期间的异位搏动次数以及冠状动脉结扎和再灌注期间心室颤动的发生率（与对照组相比，P <0.05）。综上所述，预先口服胺碘酮可抑制冠状动脉结扎/再灌注引起的心律不齐，且剂量不延长QT间隔。胺碘酮的这种抗心律不齐特性与其他三类药物的不同之处在于，在我们所有先前的研究中，抗心律不齐的作用伴随QT延长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号